Command Palette

Search for a command to run...

Clinical Trials · NCT01937598

Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D

CompletedPhase 3Liraglutide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Michael A. Nauck
Enrollment
16
Start date
Aug 2013
Locations
1 site, Germany
Primary endpoint
Incremental Area Under the Plasma Glucose (BG) Concentration-time Profile (AUC)
View Liraglutide compound reference